ミラバイオロジクス ロゴ

News

  • September 10, 2024
    We will have a booth at BioJapan, a partnering event (Location: Pacifico Yokohama, October 9 (Wed) - 11 (Fri), 2024, 10:00-17:00). We will be located at booth area, booth number: B-33, so please stop by if you are interested in our activities.
  • March 13, 2024
    March 13: We are pleased to announce that our founding director, Professor Hiroaki Suga at the University of Tokyo, received the Japan Academy Prize. This is a great accomplishment following his winning of the 2023 Wolf Prize for Chemistry last year. We would like to extend our sincere congratulations to him. For details of the Japan Academy Prize, please refer to the official website of the Japan Academy. https://www.japan-acad.go.jp/en/news/2024/031201.html
  • February 16, 2024
    [Japanese only] Our founding director, Professor Hiroaki Suga at the University of Tokyo, is scheduled to speak at the Nikkei Business Innovation Forum to be held on March 15. Pre-registration is required, and there is no charge to attend. https://events.nikkei.co.jp/65515/
  • January 30, 2024
    We participated in a partnering event, Biotech Showcase 2024 (Monday, January 8 - Wednesday, January 10, 2024 in San Francisco), where our CEO, Masuhiro Kato, gave a presentation. Please click on the link below to subscribe to the webcast and watch the video of the presentation.
  • August 21, 2023
    We will have a booth at BioJapan, a partnering event (Location: Pacifico Yokohama, October 11 (Wed) - 13 (Fri), 2023, 10:00-17:00). We will be located at booth area, booth number: C-12, so please stop by if you are interested in our activities.
  • July 1, 2023
    We have opened an official LinkdIn account for MiraBiologics, Inc. We will announce hot information about our company from time to time, so please follow us if you are interested.
  • June 27, 2023
    June 26: Our founding director, Professor Hiroaki Suga at the University of Tokyo, attended the 2023 Wolf Prize for Chemistry award ceremony held on June 15 and accepted the award. We congratulate him on receiving the prestigious Wolf Prize.
  • May 10, 2023
    May 10: We have renewed our website.
  • February 9, 2023
    Feb 9: Our founding director, Prof. Hiroaki Suga at the University of Tokyo, has been awarded the prestigious 2023 Wolf Prize in Chemistry.
  • December 5, 2022
    Feb 1 [Japanese Only] Prof. Junichi Takagi, Osaka University, and Prof. Hiroaki Suga, University of Tokyo, have contributed an article on LassoGraft Technology in "Jikken Igaku Zokan Vol. 40 No. 20, Antibody Medicine Expands Therapeutic Possibilities" published by Yodosha.
  • November 24, 2022
    Nov 24: A paper on Lassograft Technology by Associate Prof. Katsuya Sakai, Kanazawa University, Prof. Kunio Mastumoto, Kanazawa University, Prof. Junichi Takagi, Osaka University and Prof. Hiroaki Suga, University of Tokyo was introduced in the Nature biomedical engineering, “news & views” (Nat Biomed Eng, 24 Nov (2022). https://www.nature.com/articles/s41551-022-00974-3).
  • November 7, 2022
    Nov 8: A paper on Lassograft Technology by Associate Prof. Katsuya Sakai, Kanazawa University, Prof. Kunio Mastumoto, Kanazawa University, Prof. Junichi Takagi, Osaka University and Prof. Hiroaki Suga, University of Tokyo was published in the Nature biomedical engineering (Nat Biomed Eng, 07 Nov (2022). https://doi.org/10.1038/s41551-022-00955-6).
  • August 10, 2021
    Aug 10: Our Company entered into a drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. (TSE First Section: Securities Code 4528) to create next-generation biopharmaceuticals using our proprietary LassoGraft Technology that integrates cyclic peptide discovery method (RaPID System) with protein engineering (PDF attached).
  • March 10, 2021
    Mar 9: A paper on Lassograft Technology by Prof. Junichi Takagi, Osaka University, and Prof. Hiroaki Suga, University of Tokyo was published in the Nature Communications (Nature Commun 12, 1543 (2021). https://doi.org/10.1038/s41467-021-21875-0).
  • June 29, 2020
    Jun 29:  Our company has been selected for NEDO’s (New Energy and Industrial Technology Development Organization) FY2020 “Research and Development Venture Support Program / Commercialization Support for Research and Development Ventures at Seed Stage”. The title of the grant is “Verification of the Pharmaceutical Properties of Met Agonists for the Treatment of NASH” and we will promote our own development project.
  • January 17, 2020
    Feb 8 [Japanese Only] President Kato appeared at BS Fuji “konokuninoyukusue2 (every Saturday from 18:00 to 18:30)”, introduced our business (Part 2).
  • January 17, 2020
    Feb 1 [Japanese Only] President Kato appeared at BS Fuji “konokuninoyukusue2 (every Saturday from 18:00 to 18:30)”, introduced our business (Part 1).